# P3: EphA2 Targeting in Uterine Carcinoma

> **NIH NIH P50** · UNIVERSITY OF TX MD ANDERSON CAN CTR · 2020 · $162,000

## Abstract

PROJECT SUMMARY
The 2019 novel coronavirus, SARS-CoV-2 causes COVID-19, a pandemic viral disease. This disease has
resulted in world-wide fatalities, particularly in patients with cardiovascular disease, and arterial hypertension.
As of June 2020, close to 6.6 million cases and death of 393,000 were reported worldwide; 1.95 million cases
and more than 111,000 deaths in the US. COVID-19 poses a specific and substantial immediate burden on
cancer patients who are already facing the tribulations of cancer treatment and survivorship. SARS-CoV-2 will
continue to be a major threat to the lives of the above high risk groups including current and future cancer patients
irrespective of the type and stage of cancer, unless a treatment that does not interfere with current cancer
chemotherapies is developed urgently. CoVs are enveloped with a positive sense, single-strand RNA genome;
and belong to the Coronaviridae family. CoVs are composed of at least 5 major fundamental proteins: replicase
encoding polypeptide (pp1ab), Spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. The viral
life cycle begins with the infection, entry of the virion into cells by the binding to the host cell receptor and
endocytosis (S protein), release of the viral genome into the cytoplasm and its transport to the host nucleus (N
protein) where it replicates (pp1ab) and new virus particles are released. This results in respiratory, enteric,
hepatic, and neurologic diseases. pp1ab, E and N proteins, unique to SARS-CoV-2 and not natively expressed
in mammalian cells, offer potential opportunities for therapeutic targeting to cure COVID-19. Current drug and
treatment strategies include blocking of RNA-polymerase, mRNA-based vaccines to induce antibody production,
antibody treatments, and isolation of plasma and antibodies from the survivors of Covid-19. Since there are
several unwarranted side effects of targeting the proteins essential to SARS-CoV-2 infection and spread, limited
benefits of the current drugs, and limited availability of COVID-19 disease animal models, our strategy is to use
and prioritize siRNA candidates based on the greatest inhibition of SARS-CoV-2 proteins (in model cell lines
transfected with individual SARS-CoV-2 proteins) for further evaluation. We aim to use the siRNA-based
therapeutic candidates with either an aerosolized (through a collision nebulizer) neutral phospholipid 1,2-
dioleoyl-sn-glycero-3-phosphatidylcholine
target the vital proteins of SARS-CoV-2 to
nanoliposomes (DOPC) or plant-derived vesicles (PDV) to specifically
inhibit its replication and virus assembly. We expect this approach will
have a potent anti-viral RNAi response leading to viral clearance.

## Key facts

- **NIH application ID:** 10268439
- **Project number:** 3P50CA098258-15S2
- **Recipient organization:** UNIVERSITY OF TX MD ANDERSON CAN CTR
- **Principal Investigator:** ANIL K SOOD
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $162,000
- **Award type:** 3
- **Project period:** 2003-09-01 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10268439

## Citation

> US National Institutes of Health, RePORTER application 10268439, P3: EphA2 Targeting in Uterine Carcinoma (3P50CA098258-15S2). Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/grant/nih/10268439. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*